BioWorld MedTech

Oct. 16, 2012

Agreements/contracts: BD Diag, Lab21 in accord to develop cancer detection assays

It only took one successful assay developed by BD Diagnostics (Circle Sparks, Maryland) and Lab21 (Cambridge, UK), for both firms to realize they had something special when it comes to working together to get new products to market. Read More

Washington roundup: Anthem: MP-RAGE MRI a no-go for all indications

Report from Europe: Critical Diagnostics signs four partners for Presage

ICU Medical launches NanoClave connector

Deals roundup: The Gores Group to acquire Therakos from Ortho-Clinical

Grants roundup: Cardinal Health invites providers to apply for patient safety grants

Patent watch: nContact reaches milestone with new coverage of devices

Med-Tech Notes

Product Briefs

People in the News

MDD's Cardio Extra

Today's news in brief

BioWorld

BioWorld briefs for May 20, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...